Back to top

Press Releases

The Zacks Analyst Blog Highlights: UnitedHealth Group, Aetna, WellPoint, CIGNA and Wright Medical Group

UNH AET WLP CI WMGI

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

For Immediate Release

Chicago, IL – January 11, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include UnitedHealth Group Inc. ( (UNH - Analyst Report), Aetna Inc. ( (AET - Analyst Report), WellPoint Inc. ( (WLP - Analyst Report), CIGNA Corp. ( (CI - Analyst Report) and Wright Medical Group ( (WMGI - Analyst Report).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s Analyst Blog:

UNH Ends 2011 Better than Expected

UnitedHealth Group Inc. ( (UNH - Analyst Report) managed to perform quite well in 2011, in contrast to analyst predictions that the stock might be under pressure, given the challenges posed by the HealthCare law and pressure on its government programs like Medicare and Medicaid.

The stock of the biggest insurer (on the basis of revenue) gained 38% in 2011 compared with 15% in 2010, a year in which Health Care Reform was signed into law and 13% in 2009, the year which saw heated debates over the Health Care reform.

UnitedHealth also managed to perform well versus its peers Aetna Inc. ( (AET - Analyst Report), WellPoint Inc. ( (WLP - Analyst Report), CIGNA Corp. ( (CI - Analyst Report), which saw surges of 37%, 16% and 11%, respectively, in 2011.

Considering that new provisions relating to unreasonable premium increases, adherence to minimum medical loss ratios (“MLR”) and denying coverage to pre-existing diseases would pressurize its earnings, UnitedHealth spent $4.9 million in 2009, on lobbying against the reform. It spent $2.5 million in 2010 and $2.2 million in 2011 to try and water down the reforms.

The law's impact on UnitedHealth’s business model and operating fundamentals turned out to be quite manageable, albeit still subject to uncertainty. The mandate regarding minimum MLR that went into effect at the start of 2011 did not have a major effect on the company’s bottom line.

UnitedHealth was also able to post better-than-expected results throughout 2011, attributable to low medical claim costs, as Americans delayed doctor visits and medical procedures in the face of a weak economy.

In order to position itself for long-term growth, given the Health Care Reform challenges, UnitedHealth continued to focus on shifting more of its earnings to faster growing and less regulated health-related service (non-insurance) businesses, with the goal of ultimately making 30%-40% of operating income, up from about 20% currently.

It believes that demand for consulting services, data management, information technology and related infrastructure development, disease management, and population-based health and wellness programs will continue to grow. It also continues to focus on Medicaid/state program business, highlighting the significant upcoming opportunities and capabilities that a diversified carrier could offer to state governments looking to move the program to managed care.

UnitedHealth expects its 2012 EPS to be in the range of $4.55-$4.75 and revenues in the $107.0 billion-$108.0 billion range, up approximately 6.5% from the 2011 revenue guidance of more than $101 billion. We expect the company to easily achieve the targets based on its strong operating fundamentals. In fact, UnitedHealth has had a tradition of guiding conservatively and then beating the estimates to surprise investors.

Some of the factors that would boost UnitedHealth earnings in 2012 are:

Medicare, Medicaid Gains: UnitedHealth enjoys a high exposure in the Medicare market, which is expected to boom in the coming years as millions of Americans will enter the retirement age. Moreover, with the acquisition of XLHealth, the company will further strengthen its position in the Medicare Advantage market, compelling long-term growth.

Fast-growing Health Services segment: This business, branded under the name Optum, boasts of higher margin and is a very important part of the company’s diversification strategy. For the nine months ended September 30, 2011, the segment delivered approximately 18% growth. Now with the expansion of the health service business, management expects the revenue contribution to approximately double over time.

Strong balance sheet: The insurer enjoys a solid balance sheet with adequate financial flexibility and a favorable debt ratio, which helps it take decisions on acquisitions easily. Moreover, UnitedHealth has opted for shareholder-friendly measures for managing capital such as dividend payment and share buybacks.

 UnitedHealth currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. However, considering the fundamentals, we are maintaining our long-term Outperform recommendation on the shares.

Wright Launches New Products

International orthopedic devices company Wright Medical Group ( (WMGI - Analyst Report) revealed the release of its Quickdraw Knotless Soft Tissue Fixation System and the Ortholoc 3Di Ankle Fracture System. The two offerings will be sold in certain ex-U.S. countries via Wright Medical Group’s distributor-based as well as direct sales force. These offerings will be immediately available in the domestic market thanks to the company’s dedicated foot and ankle sales team.   

Quickdraw Soft Tissue Fixation System, which is based on Arthocare’s prominent Opus knotless suturing know-how, is a solution for a number of soft tissue re-joining procedures pertaining to the foot and ankle. Such procedures number more than a quarter of a million every year in the U.S. The system is comprised of the Mini-Belay and Belay knotless suture anchors and Rappel-line surgical suture and instrumentation, which is intended to safely and rapidly fixate broken or reattach tendons in the ankle and foot, including the restoration of the Achilles tendon.  

The Ortholoc 3Di Ankle Fracture System is a complete solitary-tray ankle fracture offering intended to tackle a wide array of fractures. It utilizes the Ortholoc 3Di polyaxial locking know-how, which has features that allow the surgeon to match the ideal implant with the type of fracture. This ability can cut down on complications in the operation theater. Fractured ankles are a common foot injury and about 170,000 such injuries are surgically treated each year.   

In a major move, Wright Medical recently announced that it is exercising a cost restructuring initiative to improve profitability, promote growth and strengthen cash flow, leading to enhanced shareholder value. The restructuring initiative will lead to a more cost efficient enterprise, which will boost earnings in 2012.

As per the plan, Wright Medical has launched several measures to curtail expenditure, including cutting down the range of its overseas product offerings, streamlining its R&D efforts, fine tuning factory operations and reducing headcount.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com

http://www.zacks.com

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
VERTEX ENERG VTNR 8.28 +10.99%
MODINE MANUF MOD 17.19 +9.21%
CLAYTON WILL CWEI 140.21 +7.41%
KNIGHTSBRIDG VLCCF 13.26 +5.70%
CANADIAN SOL CSIQ 30.74 +5.24%